What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Chronic Wasting Disease in Deer: Prion Biology and Emerging Diagnostic Tools

Introduction

Chronic wasting disease (CWD) is a progressive, fatal neurodegenerative disorder affecting members of the family Cervidae, including white-tailed deer (Odocoileus virginianus), mule deer (Odocoileus hemionus), elk (Cervus canadensis), moose (Alces alces), and reindeer (Rangifer tarandus). The disease is classified as a transmissible spongiform encephalopathy (TSE) and is caused by the misfolding of the cellular prion protein (PrPC) into a pathogenic isoform designated PrPCWD [1, 2]. Unlike classical infectious pathogens such as viruses or bacteria, prions are proteinaceous infectious particles that propagate through conformational templating, a mechanism that challenges conventional diagnostic paradigms [3]. CWD is unique among TSEs because of its high horizontal transmissibility through environmental contamination and its expanding geographic range across North America, Scandinavia, and South Korea [4, 5]. This article provides a detailed examination of prion biology in the context of CWD, the pathophysiological mechanisms of disease progression, and the emerging diagnostic tools that are reshaping surveillance and management strategies.

Prion Biology and Molecular Mechanisms

Structure and Conformation of PrPC and PrPCWD

The cellular prion protein (PrPC) is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed predominantly on the surface of neurons and lymphoid cells [6]. In cervids, PrPC is encoded by the PRNP gene, which exhibits polymorphisms that influence susceptibility to CWD [7]. The normal protein is characterized by a predominantly alpha-helical secondary structure, with three alpha-helices and a short antiparallel beta-sheet [8]. PrPC is soluble in nondenaturing detergents and is sensitive to proteolytic digestion by proteinase K (PK) [9].

The conversion of PrPC to PrPCWD involves a profound conformational rearrangement. PrPCWD is enriched in beta-sheet content, rendering it partially resistant to PK digestion and prone to aggregation into insoluble amyloid fibrils [10]. The templated conversion mechanism posits that PrPCWD acts as a seed that recruits and refolds PrPC molecules into the pathogenic conformation, a process that can be amplified in vitro using techniques such as real-time quaking-induced conversion (RT-QuIC) [11]. The structural transition is thermodynamically driven by the higher stability of the beta-sheet-rich aggregate state, although the precise atomic-level structure of PrPCWD remains incompletely resolved [12].

Strain Diversity and Host Range

Prion strains are defined by distinct conformational variants of PrPCWD that produce characteristic patterns of neuropathology, incubation periods, and biochemical properties such as glycosylation profiles and PK cleavage sites [13]. In CWD, multiple strains have been identified in different cervid species and geographic regions. For example, strains from mule deer and white-tailed deer exhibit differences in conformational stability and neurotropism [14]. The emergence of CWD in Norwegian reindeer and moose has revealed novel strain phenotypes that differ from North American isolates, suggesting independent emergence events or host-driven selection [15].

The host range of CWD is primarily restricted to cervids, but experimental transmission to nonhuman primates and transgenic mice expressing human PRNP has raised concerns about zoonotic potential [16]. However, no natural transmission to humans has been documented, and substantial species barriers appear to exist [17]. The molecular basis of the species barrier involves sequence homology between the donor PrPCWD and the recipient PrPC, as well as the conformational compatibility of the prion seed [18].

Pathogenesis and Transmission

Routes of Infection and Tissue Tropism

CWD is transmitted through direct contact with infected animals and indirectly through environmental contamination with saliva, urine, feces, and carcass material [19]. Prions bind avidly to soil particles, particularly clay minerals, and remain infectious for years, facilitating long-term environmental persistence [20]. The oral route is considered the primary natural route of infection, with prions crossing the intestinal epithelium via M cells and follicular dendritic cells in Peyer's patches [21].

Following oral exposure, PrPCWD accumulates in gut-associated lymphoid tissues (GALT) and then spreads to peripheral lymph nodes, tonsils, and the spleen via the lymphatic system [22]. This extraneural replication phase is critical for early detection, as lymphoid tissues become positive for PrPCWD months to years before the onset of clinical signs [23]. Neuroinvasion occurs through the autonomic and sensory nerves innervating the gut, with subsequent retrograde transport to the central nervous system (CNS) [24]. Within the CNS, PrPCWD spreads along neuroanatomical pathways, causing spongiform degeneration, astrogliosis, microglial activation, and neuronal loss [25].

Clinical Manifestations and Disease Progression

The incubation period for CWD ranges from 12 to 36 months, depending on host genetics, prion strain, and dose of exposure [26]. Clinical signs are insidious and include progressive weight loss (wasting), behavioral changes such as listlessness and social isolation, ataxia, tremors, polydipsia, polyuria, and excessive salivation [27]. Once clinical signs appear, the disease is invariably fatal within weeks to months. Subclinical carriers, particularly in early stages, represent a significant challenge for surveillance because they shed prions into the environment without exhibiting overt illness [28].

Diagnostic Approaches

Antemortem Diagnostics

Antemortem diagnosis of CWD relies on detection of PrPCWD in easily accessible tissues or body fluids. Rectal mucosa biopsy and tonsillar biopsy are established methods for live animal testing, as lymphoid follicles in these tissues accumulate PrPCWD during the preclinical phase [29]. Immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded biopsy specimens remains the gold standard for confirmatory diagnosis, with sensitivity approaching 90% in preclinical animals [30].

Enzyme-linked immunosorbent assays (ELISAs) have been developed for high-throughput screening of lymphoid tissue homogenates. These assays typically use monoclonal antibodies directed against conformational epitopes of PrPCWD and incorporate a PK digestion step to eliminate PrPC [31]. Commercial ELISA kits are widely used in surveillance programs, but they require validation against IHC and may exhibit reduced sensitivity in certain genotypes or strains [32]. For a detailed discussion of ELISA principles in veterinary diagnostics, refer to the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus.

Real-Time Quaking-Induced Conversion (RT-QuIC)

RT-QuIC is a cell-free amplification technology that exploits the seeded polymerization of PrPCWD. In this assay, a sample containing PrPCWD is incubated with recombinant PrPC substrate, and the aggregation of amyloid fibrils is monitored in real time using thioflavin T fluorescence [33]. RT-QuIC has demonstrated exceptional sensitivity and specificity for CWD detection in a variety of sample types, including cerebrospinal fluid (CSF), nasal brushings, saliva, urine, and feces [34, 35]. The assay can detect as few as 10 femtograms of PrPCWD, making it orders of magnitude more sensitive than ELISA or IHC [36].

The diagnostic workflow for RT-QuIC involves sample preparation, substrate optimization, and kinetic analysis. Positive samples produce a characteristic sigmoidal fluorescence curve, with lag phase duration inversely proportional to prion seed concentration [37]. The assay can be performed in 96-well plate format, enabling high-throughput screening. However, standardization across laboratories remains a challenge due to variability in recombinant substrate quality, buffer composition, and instrument parameters [38].

Postmortem Diagnostics

Postmortem diagnosis is typically performed on obex (medulla oblongata) and retropharyngeal lymph nodes. IHC on these tissues provides definitive diagnosis and is the prescribed method for official CWD surveillance in many jurisdictions [39]. Western blotting for PK-resistant PrPCWD is used as a confirmatory technique, particularly for research purposes, but is less practical for large-scale surveillance due to lower throughput [40].

Emerging Molecular and Proteomic Tools

Advances in proteomics and high-resolution mass spectrometry have enabled the identification of PrPCWD-specific peptide signatures in complex biological matrices [41]. These methods offer the potential for confirmatory diagnosis without reliance on antibody-based detection. Additionally, aptamer-based biosensors and surface-enhanced Raman spectroscopy (SERS) platforms are under development for rapid, point-of-care detection of prions in field settings [42, 43].

Surveillance and Management Implications

Geographic Distribution and Epidemiological Trends

CWD was first identified in captive mule deer in Colorado in the 1960s and has since spread to at least 26 U.S. states, three Canadian provinces, South Korea, and Scandinavia [44]. The expansion of CWD is driven by both natural movement of infected cervids and human-mediated translocation of carcasses and live animals [45]. Surveillance programs rely on a combination of hunter-harvested sampling, targeted culling, and roadkill testing [46].

Diagnostic Algorithm for CWD Surveillance

The following Mermaid diagram illustrates a typical diagnostic algorithm for CWD surveillance in free-ranging and captive cervids.

flowchart TD
    A[Sample Collection], > B{Antemortem or Postmortem?}
    B, >|Antemortem| C[Rectal Mucosa Biopsy / Nasal Brush]
    B, >|Postmortem| D[Obex / Retropharyngeal Lymph Node]
    C, > E[RT-QuIC or ELISA Screening]
    D, > F[IHC or ELISA Screening]
    E, > G{Positive?}
    F, > G
    G, >|Yes| H[Confirmatory IHC or Western Blot]
    G, >|No| I[Report Negative]
    H, > J{Confirmed Positive?}
    J, >|Yes| K[Report Positive / Implement Management Actions]
    J, >|No| L[Inconclusive / Retest]
    K, > M[Surveillance Data Integration]
    I, > M
    L, > C

Challenges in Eradication and Control

No vaccine or treatment exists for CWD. Control measures focus on reducing prevalence through targeted culling, movement restrictions, and enhanced biosecurity on captive facilities [47]. Environmental decontamination is extremely difficult because prions resist standard disinfection methods, including autoclaving, formaldehyde, and ionizing radiation [48]. The long environmental persistence of prions complicates efforts to eradicate CWD from endemic areas [49].

Future Directions

Research priorities include the development of portable RT-QuIC devices for field deployment, the identification of blood-based biomarkers for early detection, and the application of computational modeling to predict CWD spread under different management scenarios [50]. The integration of genomic surveillance with diagnostic data will improve understanding of host susceptibility and strain evolution. Cross-disciplinary collaboration between wildlife biologists, molecular diagnosticians, and computational biologists is essential to address the growing threat of CWD to cervid populations and ecosystem health.

References

[1] Prusiner SB. Prions. Proceedings of the National Academy of Sciences. 1998;95(23):13363-13383.

[2] Williams ES, Young S. Chronic wasting disease of captive mule deer: a spongiform encephalopathy. Journal of Wildlife Diseases. 1980;16(1):89-98.

[3] Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annual Review of Neuroscience. 2001;24:519-550.

[4] Saunders SE, Bartelt-Hunt SL, Bartz JC. Occurrence, transmission, and zoonotic potential of chronic wasting disease. Emerging Infectious Diseases. 2012;18(3):369-376.

[5] Benestad SL, Mitchell G, Simmons M, Ytrehus B, Vikoren T. First case of chronic wasting disease in Europe in a Norwegian free-ranging reindeer. Veterinary Research. 2016;47(1):88.

[6] Stahl N, Borchelt DR, Hsiao K, Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell. 1987;51(2):229-240.

[7] O'Rourke KI, Besser TE, Miller MW, et al. PRNP polymorphisms in elk and white-tailed deer associated with chronic wasting disease susceptibility. Journal of General Virology. 2004;85(Pt 5):1339-1346.

[8] Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. NMR structure of the mouse prion protein domain PrP(121-231). Nature. 1996;382(6587):180-182.

[9] Meyer RK, McKinley MP, Bowman KA, Braunfeld MB, Barry RA, Prusiner SB. Separation and properties of cellular and scrapie prion proteins. Proceedings of the National Academy of Sciences. 1986;83(8):2310-2314.

[10] Pan KM, Baldwin M, Nguyen J, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proceedings of the National Academy of Sciences. 1993;90(23):10962-10966.

[11] Atarashi R, Moore RA, Sim VL, et al. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nature Methods. 2007;4(8):645-650.

[12] Wille H, Requena JR. The structure of PrPSc prions. Pathogens. 2018;7(1):20.

[13] Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. Journal of Virology. 1994;68(12):7859-7868.

[14] Angers RC, Kang HE, Napier D, et al. Prion strain mutation determined by prion protein conformational compatibility and primary structure. Science. 2010;328(5982):1154-1158.

[15] Nonno R, Di Bari MA, Pirisinu L, et al. Studies in bank voles reveal strain differences between chronic wasting disease prions from Norwegian and North American cervids. Proceedings of the National Academy of Sciences. 2020;117(49):31417-31426.

[16] Race B, Meade-White KD, Miller MW, et al. Susceptibilities of nonhuman primates to chronic wasting disease. Emerging Infectious Diseases. 2009;15(9):1366-1376.

[17] Sandberg MK, Al-Doujaily H, Sigurdson CJ, et al. Chronic wasting disease prions are not transmissible to transgenic mice overexpressing human prion protein. Journal of General Virology. 2010;91(Pt 10):2651-2657.

[18] Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proceedings of the National Academy of Sciences. 1999;96(26):15137-15142.

[19] Mathiason CK, Powers JG, Dahmes SJ, et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science. 2006;314(5796):133-136.

[20] Johnson CJ, Phillips KE, Schramm PT, McKenzie D, Aiken JM, Pedersen JA. Prions adhere to soil minerals and remain infectious. PLoS Pathogens. 2006;2(4):e32.

[21] Heppner FL, Christ AD, Klein MA, et al. Transepithelial prion transport by M cells. Nature Medicine. 2001;7(9):976-977.

[22] Sigurdson CJ, Williams ES, Miller MW, Spraker TR, O'Rourke KI, Hoover EA. Oral transmission and early lymphoid tropism of chronic wasting disease PrPres in mule deer fawns. Journal of General Virology. 1999;80(Pt 10):2757-2764.

[23] Keane DP, Barr DJ, Bochsler PN, et al. Chronic wasting disease in a Wisconsin white-tailed deer farm. Journal of Veterinary Diagnostic Investigation. 2008;20(5):650-653.

[24] Kimberlin RH, Walker CA. Pathogenesis of scrapie in mice after intragastric infection. Virus Research. 1989;12(3):213-220.

[25] Williams ES, Miller MW. Chronic wasting disease in deer and elk in North America. Revue Scientifique et Technique. 2002;21(1):305-316.

[26] Miller MW, Williams ES. Chronic wasting disease in mule deer: disease dynamics and control. Journal of Wildlife Management. 2003;67(4):762-772.

[27] Williams ES. Chronic wasting disease. Veterinary Pathology. 2005;42(5):530-549.

[28] Henderson DM, Davenport KA, Haley NJ, et al. Quantitative assessment of prion shedding in deer with chronic wasting disease. Journal of Virology. 2015;89(5):2842-2853.

[29] Wolfe LL, Spraker TR, Gonzalez L, et al. PrPCWD in rectal lymphoid tissue of deer with chronic wasting disease. Journal of General Virology. 2007;88(Pt 7):2078-2082.

[30] Spraker TR, VerCauteren KC, Gidlewski T, et al. Antemortem detection of PrPCWD in rectal mucosa of white-tailed deer. Journal of Wildlife Diseases. 2006;42(3):529-538.

[31] Hibler CP, Wilson KL, Spraker TR, et al. Field validation and assessment of an enzyme-linked immunosorbent assay for detecting chronic wasting disease in mule deer. Journal of Veterinary Diagnostic Investigation. 2003;15(4):311-319.

[32] Haley NJ, Hoover EA. Chronic wasting disease of cervids: current knowledge and future perspectives. Annual Review of Animal Biosciences. 2015;3:305-325.

[33] Wilham JM, Orru CD, Bessen RA, et al. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassay. PLoS Pathogens. 2010;6(12):e1001217.

[34] Orru CD, Wilham JM, Raymond LD, et al. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. mBio. 2011;2(3):e00078-11.

[35] Haley NJ, Siepker C, Hoon-Hanks LL, et al. Detection of chronic wasting disease in the lymph nodes of free-ranging cervids by real-time quaking-induced conversion. Journal of Clinical Microbiology. 2016;54(12):2954-2961.

[36] Henderson DM, Manca M, Haley NJ, et al. Rapid antemortem detection of CWD prions in deer saliva. PLoS One. 2013;8(9):e74377.

[37] Orru CD, Groveman BR, Raymond LD, et al. Bank vole prion protein as a broadly reactive substrate for RT-QuIC detection of prions. Journal of General Virology. 2015;96(Pt 7):1910-1921.

[38] Cramm M, Schmitz M, Karch A, et al. Stability and reproducibility of RT-QuIC assays for prion detection. Journal of Clinical Microbiology. 2016;54(8):2028-2035.

[39] Miller MW, Williams ES, McCarty CW, et al. Evaluation of a rapid test for chronic wasting disease in mule deer. Journal of Wildlife Diseases. 2002;38(4):731-737.

[40] Race RE, Ernst D. Detection of proteinase K-resistant prion protein in the brains of deer with chronic wasting disease. Journal of Veterinary Diagnostic Investigation. 1992;4(4):424-428.

[41] Silva CJ, Erickson-Beltran ML, Duque Velasquez C, et al. Mass spectrometric detection of prion protein in the blood of deer with chronic wasting disease. Journal of Proteome Research. 2014;13(11):5085-5094.

[42] Xiao SJ, Hu PP, Wu XD, et al. Aptamer-based biosensor for prion protein detection. Analytical Chemistry. 2009;81(9):3616-3622.

[43] Alvarez-Puebla RA, Liz-Marzan LM. SERS-based diagnosis and biodetection. Small. 2010;6(5):604-610.

[44] Richards BJ, Bartz JC, Bessen RA, et al. Geographic distribution of chronic wasting disease in North America. Journal of Wildlife Diseases. 2021;57(1):1-12.

[45] Edmunds DR, Kauffman MJ, Schumaker BA, et al. Chronic wasting disease drives population decline of white-tailed deer. PLoS One. 2016;11(8):e0161127.

[46] Heisey DM, Joly DO, Messier F. The fitting of general force-of-infection models to wildlife disease data. Ecology. 2006;87(9):2356-2365.

[47] VerCauteren KC, Lavelle MJ, Phillips GE, et al. Management of chronic wasting disease in free-ranging cervids. Wildlife Society Bulletin. 2018;42(2):234-243.

[48] Taylor DM. Inactivation of transmissible degenerative encephalopathy agents: a review. Veterinary Journal. 2000;159(1):10-17.

[49] Bartelt-Hunt SL, Bartz JC. Behavior of prions in the environment: implications for prion biology. Prion. 2013;7(3):192-198.

[50] Almberg ES, Cross PC, Johnson CJ, Heisey DM, Richards BJ. Modeling routes of chronic wasting disease transmission: environmental prion persistence and deer movement. Ecological Applications. 2011;21(7):2638-2651.